9-氨基-1,2,3,4-四氢吖啶-4-醇 | 130073-99-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 9-氨基-1,2,3,4-四氢吖啶-4-醇
• 英文名称: 9-Amino-1,2,3,4-tetrahydroacridin-4-ol
• 英文别名: 4-Hydroxytacrine；9-amino-1,2,3,4-tetrahydroacridine-4-ol
• CAS: 130073-99-3
• 化学式: C₁₃H₁₄N₂O
• 分子量: 214.267
• InChiKey: BISIFJGUTDFVFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  3

ADMET

代谢

4-羟基他克林是已知的人体他克林的代谢物。

4- Hydroxytacrine is a known human metabolite of tacrine.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  9-氨基-1,2,3,4-四氢吖啶-4-醇 以 乙酸酐 为溶剂， 生成 4-Acetoxy-1,2,3,4-tetrahydro-9-acridinamine fumarate
  参考文献：
  名称：

  Hydroxy-1,2,3,4-tetrahydroaminoacridines, a process for their preparation and their use as medicaments

  摘要：

  公开号：

  EP0369388B1
• 作为产物：
  描述：

  4-hydroxy-9-methoxycarbonylamino-1,2,3,4-tetrahydroacridine 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以64%的产率得到9-氨基-1,2,3,4-四氢吖啶-4-醇
  参考文献：
  名称：

  9-氨基-，9-氨基甲基-1,2,3,4-四氢-和1,2,3,4,5,6,7,8-八氢ac啶衍生物的合成

  摘要：

  本文描述了9-氨基-2-和4-羟基-和2,4-二羟基-1,2,3,4-四氢-啶2和9-氨基甲基-1,2,3,4-的合成从相应的9-羧酰胺基衍生物开始的四氢和1,2,3,4,5,6,7,8-八氢ac啶3。还报道了一种新的合成途径，可合成9-氨基-2-羟基a啶二酮9。

  DOI：

  10.1002/jhet.5570340604

文献信息

• [EN] NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS MICROBICIDES D'ÉTHER DE DIOXIME
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2012001040A1

  公开（公告）日：2012-01-05

  The present invention provides compounds of formula (I) wherein R1, A1, X, Y6, Y7, Y8, G1, G2, G3 and p are as defined in the claims. The invention further provides intermediates used in the preparation of these compounds, to compositions which comprise these compounds and to their use in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

  本发明提供了以下式（I）的化合物，其中R1、A1、X、Y6、Y7、Y8、G1、G2、G3和p如权利要求中所定义。本发明还提供了用于制备这些化合物的中间体，以及包含这些化合物的组合物，并将其用于农业或园艺中，以控制或预防植物受植物病原微生物，尤其是真菌的侵害。
• Simultaneous Determination of Tacrine and 1‐Hydroxy‐, 2‐Hydroxy‐, and 4‐Hydroxytacrine in Human Plasma by High‐Performance Liquid Chromatography with Fluorescence Detection
  作者：David B. Haughey、Patricia M. Klockowski、Mary S. Collis、Richard R. Brown、Paul H. Siedlik、Colleen A. McNaney、Linda Balogh

  DOI：10.1002/jps.2600831113

  日期：1994.11

  An analytical method was developed for the simultaneous reversed-phase (cyano) high-performance liquid chromatographic determination with fluorescence detection of tacrine and 1-hydroxy-, 2-hydroxy-, and 4-hydroxytacrine in human plasma. Alkalinized human plasma samples were extracted with a mixture of chloroform/l-propanol (90:10, v/v). Extraction recoveries generally ranged from 68% to 83% for all

  开发了一种分析方法，用于同时反相（氰基）高效液相色谱测定，并通过荧光检测人血浆中的他克林和1-羟基，2-羟基和4-羟基他克林。用氯仿/ 1-丙醇（90：10，v / v）的混合物提取碱化的人血浆样品。对于所有四种化合物，提取回收率通常在68％至83％的范围内，并且在所检查的范围内似乎与浓度无关。在以下范围内构建校正曲线：他克林（THA）和4-羟基他克林（4-OH-THA）为0.5-30.0 ng / mL，2-羟基他克林（2-OH-THA）为1.0-30.0 ng / mL， 1-羟基他克林（1-OH-THA）的浓度为0.925-46.2 ng / mL。验证期间分析的质量控制样品的测定内和测定间精密度（RSD）≤11.8％和< 或分别为9.28％。对于所有四种化合物，在验证过程中分析的质量控制样品的测定内和测定间准确度（RE）分别在14.1％至-7.5％和12.1％至-3.33％之间。基
• NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES
  申请人：Nebel Kurt

  公开号：US20130102631A1

  公开（公告）日：2013-04-25

  The present invention provides compounds of formula (I) wherein R 1 , A 1 , X, Y 6 , Y 7 , Y 8 , G 1 , G 2 , G 3 and p are as defined in the claims. The invention further provides intermediates used in the preparation of these compounds, to compositions which comprise these compounds and to their use in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

  本发明提供公式(I)中的化合物，其中R1，A1，X，Y6，Y7，Y8，G1，G2，G3和p如权利要求书所定义。本发明还提供用于制备这些化合物的中间体，包括这些化合物的组合物以及它们在农业或园艺中用于控制或预防植物被植物病原微生物，优选为真菌侵染。
• 4-aminopyridine derivatives
  申请人：PFIZER INC.

  公开号：EP0311303A2

  公开（公告）日：1989-04-12

  Compounds of the formula wherein A, B, R¹ and R² are defined below. The above compounds inhibit brain acetylcholine­sterase and are useful in the treatment of Alzheimer's disease.

  式中的化合物 其中 A、B、R¹ 和 R² 的定义如下。 上述化合物能抑制脑乙酰胆碱酯酶，可用于治疗阿尔茨海默氏症。
• Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver:<i>in vitro/in vivo</i>comparisons
  作者：M. Kukan、Š. Bezek、W. F. Pool、T. F. Woolf

  DOI：10.3109/00498259409038670

  日期：1994.1

  1. Incubations of tacrine (1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate, THA) with a primary suspension of rat hepatocytes for 2 min resulted in formation of the l-hydroxy derivative as the major metabolite with smaller amounts of the 2- and 4-hydroxy metabolites.2. Apparent V-max and K-m for THA metabolism were 12.4 +/- 3.3 nmol/min/g liver and 0.98 +/- 0.34 mu M respectively.3. Incubations of THA for longer time-periods (> 10 min) resulted in irreversible binding of THA-derived radioactivity to hepatocellular protein. The apparent maximal rate of irreversible binding (B-max) was 76.7 +/- 30.5 pmol equivalents bound/h/mg cell protein, whereas the apparent K-b for binding was 2.8 +/- 1.4 mu M.4. The kinetic parameters, V-max and K-m, were used to predict steady-state extraction ratios (ER(ss)) for various THA input concentrations (C-in) in single-pass perfused rat liver. At low input concentrations (0.72-0.85 mu M; C-in < K-m), ER(ss) of THA was approximately 1. For higher C-in (14.05, 20.72, 20.88 mu M; C-in, much greater than K-m), the calculated ER(ss) was markedly decreased with 0.300, 0.296 and 0.261, respectively.5. The intrinsic clearance of THA (Cl-i) estimated from in vitro hepatocyte data was 6.7 ml/min/g liver while the apparent oral THA clearance (Cl-oral) calculated from in vivo rat data was 6.6 ml/min/g liver.